Literature DB >> 30946085

Conditional Survival in Patients With Rectal Cancer and Complete Clinical Response Managed by Watch and Wait After Chemoradiation: Recurrence Risk Over Time.

Guilherme P São Julião1, Georgios Karagkounis2, Laura M Fernandez3, Angelita Habr-Gama1,4, Bruna B Vailati1, Mit Dattani5, Matthew F Kalady2, Rodrigo O Perez1,4,6.   

Abstract

OBJECTIVE: Analyze conditional recurrence-free survival (cRFS) for rectal cancer patients with complete clinical response (cCR) after neoadjuvant chemoradiation (nCRT) managed nonoperatively after each year without recurrence. SUMMARY BACKGROUND DATA: Select patients with cCR after nCRT have been managed nonoperatively. Risk factors for local recurrence, the need for prolonged follow-up, and the risk of recurrence over time are not well defined.
METHODS: Retrospective review of patients with rectal cancer cT2-4N0-2M0 treated with nCRT. Mean follow-up was 64 months. Patients who achieved cCR were managed nonoperatively. cRFS was used to investigate the evolution of recurrence-odds, as patients remain recurrence-free after completion of nCRT. Three-year cRFS was estimated at "x" years after completion of nCRT based on the formula cRFS3 = RFS(x+3)/RFS(x).
RESULTS: One hundred ninety-seven patients with cCR after nCRT were included. Overall survival and recurrence-free survival (RFS) at 5 years were 81.9% (95% CI 74.0%-87.6%) and 60.4% (95% CI 52.5%-67.4%) respectively. Using cRFS estimates, the probability of remaining disease-free for an additional 3 years if the patient survived without disease at 1, 3, and 5 years, was 77.4% (95% CI 68.8%-83.8%), 91.0% (95% CI 81.9%-95.7%), and 94.3% (95% CI 82.9%-98.2%), respectively. In contrast, actuarial RFS rates for similar intervals were 79.1% (95% CI 72.5%-84.2%), 64.2% (95% CI 56.5%-70.8%), and 60.4% (95% CI 52.5%-67.4%). After 2 years disease-free, 3 year cRFS became similar for T2 and T3 cancers. In contrast, patients undergoing extended nCRT became less likely to develop recurrences only after initial 2 years of successful organ-preservation.
CONCLUSIONS: Conditional survival suggests that patients have significantly lower risks (≤10%) of developing recurrences after 2 years of achieving cCR following nCRT.

Entities:  

Mesh:

Year:  2020        PMID: 30946085     DOI: 10.1097/SLA.0000000000003286

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  4 in total

Review 1.  [Complete response after neoadjuvant therapy of rectal cancer: implications for surgery].

Authors:  Carolin Kastner; Bernhard Petritsch; Joachim Reibetanz; Christoph-Thomas Germer; Armin Wiegering
Journal:  Chirurg       Date:  2021-12-08       Impact factor: 0.955

2.  MRI Assessment of Complete Response to Preoperative Chemoradiation Therapy for Rectal Cancer: 2020 Guide for Practice from the Korean Society of Abdominal Radiology.

Authors:  Seong Ho Park; Seung Hyun Cho; Sang Hyun Choi; Jong Keon Jang; Min Ju Kim; Seung Ho Kim; Joon Seok Lim; Sung Kyoung Moon; Ji Hoon Park; Nieun Seo
Journal:  Korean J Radiol       Date:  2020-07       Impact factor: 3.500

Review 3.  The Role of Micro-RNAs and Circulating Tumor Markers as Predictors of Response to Neoadjuvant Therapy in Locally Advanced Rectal Cancer.

Authors:  Fatima Domenica Elisa De Palma; Gaetano Luglio; Francesca Paola Tropeano; Gianluca Pagano; Maria D'Armiento; Guido Kroemer; Maria Chiara Maiuri; Giovanni Domenico De Palma
Journal:  Int J Mol Sci       Date:  2020-09-24       Impact factor: 5.923

4.  Development and validation of a web-based calculator to predict individualized conditional risk of site-specific recurrence in nasopharyngeal carcinoma: Analysis of 10,058 endemic cases.

Authors:  Chen-Fei Wu; Jia-Wei Lv; Li Lin; Yan-Ping Mao; Bin Deng; Wei-Hong Zheng; Dan-Wan Wen; Yue Chen; Jia Kou; Fo-Ping Chen; Xing-Li Yang; Zi-Qi Zheng; Zhi-Xuan Li; Si-Si Xu; Jun Ma; Ying Sun
Journal:  Cancer Commun (Lond)       Date:  2020-12-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.